文献速递支持与姑息治疗

胰高血糖素样肽-1激动剂降低接受免疫检查点抑制剂治疗的癌症患者的心血管事件

Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.
PubMed 文献 · Eur J Cancer · 2024-12-11

该回顾性倾向评分匹配队列研究利用TriNetX数据库,纳入2013年4月至2023年5月接受免疫检查点抑制剂(ICI)且合并2型糖尿病的成人癌症患者,比较胰高血糖素样肽-1激动剂(GLP1a)组与非GLP1a降糖药组的心血管事件。匹配后每组469例,中位随访12个月,GLP1a组主要不良心血管事件(MACE)发生率显著低于非GLP1a组(每100患者年9.0 vs 17.1),MACE风险降低54%(HR 0.46,95%CI 0.32-0.67)。

要点

  • GLP1a组MACE发生率为每100患者年9.0,非GLP1a组为17.1,GLP1a组风险降低54%(HR 0.46,95%CI 0.32-0.67)。
  • 心肌梗死或需冠状动脉血运重建、心力衰竭及全因死亡率均降低,其他心血管事件无差异。
  • GLP1a未增加胰腺炎、胆道疾病、肠梗阻、胃轻瘫及免疫相关不良事件风险。

核心结论

  • 在接受ICI且合并2型糖尿病的癌症患者中,使用GLP1a与MACE及全因死亡率降低相关,且未增加严重不良事件风险。

研究设计与样本

  • 回顾性、倾向评分匹配队列研究,使用TriNetX数据库。
  • 纳入2013年4月至2023年5月接受ICI的成人癌症合并2型糖尿病患者7651例,其中479例接受GLP1a,7172例接受非GLP1a降糖药。
  • 倾向评分匹配后每组各469例,基线特征均衡。
  • 主要疗效终点为新发MACE,定义为心肌梗死、需冠状动脉血运重建、心力衰竭、缺血性卒中及心脏骤停的复合终点。
  • 次要疗效终点为MACE各组成部分以及心肌炎和心包炎;安全性终点包括免疫相关不良事件、GLP1a相关严重不良事件及全因死亡率。

主要发现

  • 中位随访12个月,GLP1a组MACE发生率为每100患者年9.0,非GLP1a组为每100患者年17.1。
  • GLP1a组MACE风险较非GLP1a组降低54%(HR 0.46,95%CI 0.32-0.67)。
  • 心肌梗死或需冠状动脉血运重建、心力衰竭及全因死亡率均降低,其他心血管事件无差异。
  • GLP1a使用未增加胰腺炎、胆道疾病、肠梗阻、胃轻瘫及免疫相关不良事件风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE). Glucagon-like peptide-1 agonists (GLP1a), initially developed for type 2 diabetes mellitus (T2DM), have shown promising results in reducing cardiovascular events. We aimed to investigate the effect of GLP1a on cardiovascular events in patients receiving ICIs. METHODS: We conducted a retrospective, propensity score-matched cohort study using the TriNetX database. We identified adults with cancer and T2DM who received ICIs between April 2013 and May 2023. The primary efficacy outcome was incident MACE, defined as a composite of myocardial infarction, need for coronary revascularization, heart failure, ischemic stroke, and cardiac arrest. The secondary efficacy outcomes were the individual components of MACE as well as myocarditis and pericarditis. Safety outcomes included the occurrence of immune-related adverse events, serious adverse events related to GLP1a use, and all-cause mortality. RESULTS: We identified 7651 patients eligible for inclusion, among which 479 received GLP1a and 7172 received non-GLP1a diabetes medications. After matching (469 patients each), baseline characteristics were well-balanced. Over a median 12-month follow-up, the GLP1a cohort had a significantly lower MACE incidence than the non-GLP1a cohort (9.0 vs. 17.1 events per 100 patient-years) with a 54 % lower risk of MACE (Hazard ratio (HR),0.46 [95 % CI: 0.32-0.67]). There were reductions in myocardial infarction or need for coronary revascularization, heart failure, and all-cause mortality, with no differences in other cardiovascular events. GLP1a use did not increase risk of adverse events, including pancreatitis, biliary disease, bowel obstruction, gastroparesis, and immune-related adverse events. CONCLUSION: GLP1a use in cancer patients with T2DM receiving ICIs was associated with reduced MACE and all-cause mortality without an increased risk in serious adverse events.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chiang CH, Song J, Chi KY, et al. Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors. Eur J Cancer. 2024. PMID: 39709670. doi:10.1016/j.ejca.2024.115170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。